Press Release – March 14th, 2017 – (PRBUZZ) – Salt Lake City, Utah, Santa Monica, CA and Brooklyn Park, Minnesota – Today Leonhardt’s Launchpads announced it has selected Biomerics LLC Utah and Biomerics Advanced Catheter Minnesota as its primary source manufacturer for a number of medical devices it has patented and developed.
These devices include:
- Second Heart Assist, Inc. aorta position circulatory assist pumps – both temporary on catheter and wireless chronic devices.
- Electrical stimulation pacing and stem cell + growth factor infusion leads for Leonhardt’s full lineup of organ regeneration devices.
- Valvublator catheter based device for decalcifying and regenerating heart valves.
This OEM contract includes;
- rapid protyotype building and testing;
- catheter design;
- circulatory assist pump assemblies;
- pacing lead and infusion catheter assemblies;
- mechanical fabrication;
- cGMP clinical manufacturing;
- quality assurance;
- packaging and arranging sterilization then shipping.
“With Leonhardt’s long standing record of major medical device innovations we are honored to be chosen as their primary OEM supplier,” remarked Steve Berhow, President of Biomerics Advanced Catheter. “At Biomerics Advanced Catheter, we’ve always taken pride in our ability to help customers propel their ideas forward. By design we are set up to serve clients, like Leonhardt, to better integrate their minimally invasive engineering technologies with large scale manufacturing solutions. I am excited about the potential to participate in potentially improving and saving lives of thousands maybe millions with Leonhardt’s breakthrough technologies and for the corresponding flow of continuous long term business for Biomerics Advanced Catheter.”
“This agreement highlights Biomerics’ commitment and presence in serving true medical innovators,” stated Travis Sessions, CEO of Biomerics, LLC. “We remain committed to providing next generation solutions to the cardiovascular, structural heart, cardiac rhythm management, electrophysiology, and neurovascular markets. Leonhardt’s Launchpads incredibly is developing innovations in ALL these areas. Our new agreement with Leonhardt is yet another step towards remaining at the forefront of design and manufacturing within these demanding market segments. That leadership position could be forged for years to come considering the depth of Leonhardt’s unprecedented innovation pipeline.”
“We set up operations in Utah in November 2015 because of the incredible infrastructure to support biomedical innovation. Biomerics is a perfect example. Earlier this month we visited their Advanced Catheter team in Minnesota, where Leonhardt Ventures began in 1982, and found their engineers to be amongst the best we have ever worked with in our history. We are highly impressed with their rapid prototyping capabilities served by unparalleled integrated operations extending from polymer design, proprietary non-thrombogenic coatings, high level extrusion, molding and complicated assembly. Their attention to detail and quality in both design and manufacturing makes them an ideal partner for us. We believe this is just the beginning of a long standing great working relationship.” stated Howard Leonhardt, Founder, Executive Chairman & CEO of Leonhardt’s Launchpads
Leonhardts’ Second Heart Assist device is expected to be the first percutaneous placed design that offers both pulsatile and continuous flow options and incorporates harmonic vibrational energy technology to reduce risk of thrombosis. The chronic support version is wirelessly powered. The Leonhardt team has entered an exclusive patent option license agreement with Caltech covering 4 issued U.S. patents and numerous others pending. The option licensed Caltech patent estate includes miniature stent pump designs and technologies designed to minimimize hemolysis, thrombosis, infection and mechanical breakdown associated with previous chronic use circulatory assist devices. The Second Heart Assist device was originally developed by the Leonhardt team to compliment their BioLeonhardt www.bioleonhardt.com heart regeneration and MyoStim Peripheral limb salvage technologies.
Biomerics, LLC specializes in the design, development, and production of finished medical devices used in diagnostic and interventional procedures. Biomerics provides complete development and manufacturing solutions for customers in the cardiovascular, structural heart, cardiac rhythm management, electrophysiology, neurovascular, vascular access, and pain management markets. Headquartered in Salt Lake City, Biomerics has operations across three ISO-13485 compliant facilities. Biomerics has a 40,000 sq. ft. facility in Salt Lake City, Utah and a 52,000 sq. ft. new start of the art building in Brooklyn Park, Minnesota specializing in Advanced Catheters – http://biomerics.com/about-us/locations/
About Leonhardt’s Launchpads:
Leonhardt’s Launchpads is an innovation accelerator focused on organ regeneration and recovery technologies with operations in California and Utah. Leonhardt’s Launchpads was formed by Leonhardt Ventures in 2008 in Northern California, opened up in Southern California in 2013 and in Utah in 2015. They currently are incubating 30 startups. Leonhardt Ventures was founded in 1982 (originally HJ Leonhardt & Co.). In the 1980’s the Leonhardt team led in patented cardiovascular balloon catheter development, in 1990’s stent grafts and percutaneous heart valves, since 2000 the focus has been on organ regeneration. The team is most well known for dominant world leadership in stent grafts for repair of aortic aneurysms without surgery, one of the first patented percutaneous heart valves and completing the first non-surgical stem cell repair of a human heart in 2001. Howard Leonhardt their founder has over 21 issued U.S. patents and a dozen more pending.